• Independent Board Member


David Nicholson, PH.D.

David has a distinguished track record of spearheading the development of over 25 new drug products throughout his extensive 40-year career in research and development. His rich expertise has been honed through various senior leadership roles at Allergan, Bayer, Merck, Schering-Plough, and Organon. Notably, Dr. Nicholson is known for his instrumental role in advancing the groundbreaking anti-PD1 cancer drug, Keytruda® (pembrolizumab), from its initial research stages to a revolutionary development in cancer therapy.